These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 38779376)
1. Putting the Formulation Back in Foam: Optimizing Seborrheic Dermatitis Treatment Across Diverse Hair Types. Chovatiya R; Polaskey MT; Lain E; Schlesinger T; Woolery-Llloyd H; Burnett P; Hanna D J Clin Aesthet Dermatol; 2024 May; 17(5):30-33. PubMed ID: 38779376 [TBL] [Abstract][Full Text] [Related]
2. When Patient Diversity Informs Formulation: Reimagining Treatment for Seborrheic Dermatitis. Polaskey MT; Woolery-Llloyd H; Osborne D; Burnett P; Hanna D; Chovatiya R Dermatol Ther (Heidelb); 2024 May; 14(5):1071-1077. PubMed ID: 38676839 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial. Zirwas MJ; Draelos ZD; DuBois J; Kircik LH; Moore AY; Stein Gold L; Alonso-Llamazares J; Bukhalo M; Bruce S; Eads K; Green LJ; Guenthner ST; Ferris LK; Forman SB; Kempers SE; Lain E; Lynde CW; Pariser DM; Toth DP; Yamauchi PS; Higham RC; Krupa D; Burnett P; Berk DR JAMA Dermatol; 2023 Jun; 159(6):613-620. PubMed ID: 37133856 [TBL] [Abstract][Full Text] [Related]
4. Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial. Blauvelt A; Draelos ZD; Stein Gold L; Alonso-Llamazares J; Bhatia N; DuBois J; Forman SB; Gooderham M; Green L; Guenthner ST; Hebert AA; Lain E; Moore AY; Papp KA; Zirwas M; Kato S; Snyder S; Krupa D; Burnett P; Berk DR; Chu DH J Am Acad Dermatol; 2024 May; 90(5):986-993. PubMed ID: 38253129 [TBL] [Abstract][Full Text] [Related]
5. A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. Elewski BE; Abramovits W; Kempers S; Schlessinger J; Rosen T; Gupta AK; Abraham S; Rowell R J Drugs Dermatol; 2007 Oct; 6(10):1001-8. PubMed ID: 17966177 [TBL] [Abstract][Full Text] [Related]
6. Seborrheic Dermatitis in Skin of Color: Clinical Considerations. Elgash M; Dlova N; Ogunleye T; Taylor SC J Drugs Dermatol; 2019 Jan; 18(1):24-27. PubMed ID: 30681789 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of betamethasone valerate 0.1% thermophobic foam in seborrhoeic dermatitis of the scalp: an open-label, multicentre, prospective trial on 180 patients. Milani M; Antonio Di Molfetta S; Gramazio R; Fiorella C; Frisario C; Fuzio E; Marzocca V; Zurilli M; Di Turi G; Felice G Curr Med Res Opin; 2003; 19(4):342-5. PubMed ID: 12841928 [TBL] [Abstract][Full Text] [Related]
8. Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis: results of a double-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage. Abeck D; Int J Dermatol; 2004 Jul; 43 Suppl 1():13-6. PubMed ID: 15271195 [TBL] [Abstract][Full Text] [Related]
10. Unmet needs for patients with seborrheic dermatitis. Jackson JM; Alexis A; Zirwas M; Taylor S J Am Acad Dermatol; 2024 Mar; 90(3):597-604. PubMed ID: 36538948 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. Lebwohl M; Plott T Int J Dermatol; 2004 Jul; 43 Suppl 1():17-20. PubMed ID: 15271196 [TBL] [Abstract][Full Text] [Related]
12. Medicated shampoos for the treatment of seborrheic dermatitis. Waldroup W; Scheinfeld N J Drugs Dermatol; 2008 Jul; 7(7):699-703. PubMed ID: 18664167 [TBL] [Abstract][Full Text] [Related]
13. A Phase III, Multicenter, Parallel-Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam Versus Vehicle in Women With Female Pattern Hair Loss. Bergfeld W; Washenik K; Callender V; Zhang P; Quiza C; Doshi U; Blume-Peytavi U J Drugs Dermatol; 2016 Jul; 15(7):874-81. PubMed ID: 27391639 [TBL] [Abstract][Full Text] [Related]
14. Applicability of Trichoscopy in Scalp Seborrheic Dermatitis. Widaty S; Pusponegoro EH; Rahmayunita G; Astriningrum R; Akhmad AM; Oktarina C; Miranda E; Agustin T Int J Trichology; 2019; 11(2):43-48. PubMed ID: 31007472 [TBL] [Abstract][Full Text] [Related]
16. Dermoscopic findings in scalp psoriasis and seborrheic dermatitis; two new signs; signet ring vessel and hidden hair. Kibar M; Aktan Ş; Bilgin M Indian J Dermatol; 2015; 60(1):41-5. PubMed ID: 25657395 [TBL] [Abstract][Full Text] [Related]
17. Ciclopirox 1% shampoo for the treatment of seborrheic dermatitis. Gupta AK; Nicol KA Int J Dermatol; 2006 Jan; 45(1):66-9. PubMed ID: 16426382 [TBL] [Abstract][Full Text] [Related]
18. Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp. Kastarinen H; Oksanen T; Okokon EO; Kiviniemi VV; Airola K; Jyrkkä J; Oravilahti T; Rannanheimo PK; Verbeek JH Cochrane Database Syst Rev; 2014 May; 2014(5):CD009446. PubMed ID: 24838779 [TBL] [Abstract][Full Text] [Related]
19. A newer approach in the treatment of seborrheic dermatitis with QR678® and QR678 Neo®-A prospective pilot study. Kapoor R; Shome D; Doshi K; Patel G; Tandel H; Kumar V J Cosmet Dermatol; 2023 Nov; 22(11):3078-3087. PubMed ID: 37621248 [TBL] [Abstract][Full Text] [Related]
20. Optimizing treatment approaches in seborrheic dermatitis. Gary G J Clin Aesthet Dermatol; 2013 Feb; 6(2):44-9. PubMed ID: 23441240 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]